Rexahn Pharmaceuticals, Inc.s in-depth stock price analysis indicates that the stock price has rallied 6.04% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -18.59% . Looking at the past 52 week period, the stock price is down -43.77% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Rexahn Pharmaceuticals, Inc. has a negative value of -57.01 compared to overall market performance. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has climbed 19.69% in the past week and advanced 22.65% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 18.73% and the outperformance has advanced to 20.46% for the last 4 weeks period.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) : On Friday heightened volatility was witnessed in Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) which led to swings in the share price. The stock opened for trading at $0.19 and hit $0.2098 on the upside , eventually ending the session at $0.2036, with a gain of 10.23% or 0.0189 points. The heightened volatility saw the trading volume jump to 4,654,870 shares. The 52-week high of the share price is $0.4245 and the company has a market cap of $48 million. The 52-week low of the share price is at $0.127 .
Company has reported several Insider transactions to the SEC, on Jan 12, 2015, Tae Heum Jeong (Chief Financial Officer) sold 317,272 shares at 0.91 per share price.On Jan 12, 2015, Chang Ho Ahn (director) sold 314,656 shares at 0.91 per share price.
REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahns compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy.